malcontented
发表于 2025-3-21 19:48:09
书目名称Handbook of Anticancer Pharmacokinetics and Pharmacodynamics影响因子(影响力)<br> http://figure.impactfactor.cn/if/?ISSN=BK0420812<br><br> <br><br>书目名称Handbook of Anticancer Pharmacokinetics and Pharmacodynamics影响因子(影响力)学科排名<br> http://figure.impactfactor.cn/ifr/?ISSN=BK0420812<br><br> <br><br>书目名称Handbook of Anticancer Pharmacokinetics and Pharmacodynamics网络公开度<br> http://figure.impactfactor.cn/at/?ISSN=BK0420812<br><br> <br><br>书目名称Handbook of Anticancer Pharmacokinetics and Pharmacodynamics网络公开度学科排名<br> http://figure.impactfactor.cn/atr/?ISSN=BK0420812<br><br> <br><br>书目名称Handbook of Anticancer Pharmacokinetics and Pharmacodynamics被引频次<br> http://figure.impactfactor.cn/tc/?ISSN=BK0420812<br><br> <br><br>书目名称Handbook of Anticancer Pharmacokinetics and Pharmacodynamics被引频次学科排名<br> http://figure.impactfactor.cn/tcr/?ISSN=BK0420812<br><br> <br><br>书目名称Handbook of Anticancer Pharmacokinetics and Pharmacodynamics年度引用<br> http://figure.impactfactor.cn/ii/?ISSN=BK0420812<br><br> <br><br>书目名称Handbook of Anticancer Pharmacokinetics and Pharmacodynamics年度引用学科排名<br> http://figure.impactfactor.cn/iir/?ISSN=BK0420812<br><br> <br><br>书目名称Handbook of Anticancer Pharmacokinetics and Pharmacodynamics读者反馈<br> http://figure.impactfactor.cn/5y/?ISSN=BK0420812<br><br> <br><br>书目名称Handbook of Anticancer Pharmacokinetics and Pharmacodynamics读者反馈学科排名<br> http://figure.impactfactor.cn/5yr/?ISSN=BK0420812<br><br> <br><br>
Directed
发表于 2025-3-22 00:00:47
http://reply.papertrans.cn/43/4209/420812/420812_2.png
browbeat
发表于 2025-3-22 04:17:18
Phase 0 Trials in Oncology,gent demonstrates a desirable pharmacokinetic/pharmacodynamic profile, traditional phase I safety and tolerability studies are conducted; otherwise, further clinical development of the agent is unlikely to be justified. This chapter summarizes the key differences between phase 0 and phase I clinical
Inflamed
发表于 2025-3-22 06:34:06
http://reply.papertrans.cn/43/4209/420812/420812_4.png
Traumatic-Grief
发表于 2025-3-22 10:46:08
Protein Binding,es in which monitoring of unbound concentrations might be useful: (1) agents demonstrating protein concentration-dependent binding, (2) agents that bind irreversible or near covalently, (3) when formulation excipients modulate unbound drug levels, and (4) metabolically interconversible agents. While
fertilizer
发表于 2025-3-22 15:58:33
Handbook of Anticancer Pharmacokinetics and Pharmacodynamics
Adherent
发表于 2025-3-22 17:11:17
The Vegetation and Physiography of Sumatraal and each has a role for specific drugs. However, no one method is a practical dose calculation strategy for many or all drugs. Neither body size nor fixed dosing alone can be used for currently available drugs. Conclusion: Dosing strategies for anticancer drugs should be individualized according
大沟
发表于 2025-3-22 23:20:18
https://doi.org/10.1007/978-94-015-8066-3gent demonstrates a desirable pharmacokinetic/pharmacodynamic profile, traditional phase I safety and tolerability studies are conducted; otherwise, further clinical development of the agent is unlikely to be justified. This chapter summarizes the key differences between phase 0 and phase I clinical
Goblet-Cells
发表于 2025-3-23 04:42:30
http://reply.papertrans.cn/43/4209/420812/420812_9.png
HARP
发表于 2025-3-23 08:52:52
http://reply.papertrans.cn/43/4209/420812/420812_10.png